{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:24:55Z","timestamp":1777883095364,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007192","name":"Rijksinstituut voor Volksgezondheid en Milieu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007192","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ejca.2026.116601","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:47:44Z","timestamp":1771919264000},"page":"116601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term cervical cancer risk following negative hrHPV-based versus negative cytology-based screening: A population-based study"],"prefix":"10.1016","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2812-6647","authenticated-orcid":false,"given":"Veerle J.C.","family":"Schevenhoven","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0436-6918","authenticated-orcid":false,"given":"Erik E.L.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-0678","authenticated-orcid":false,"given":"Albert G.","family":"Siebers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9419-0452","authenticated-orcid":false,"given":"Inge M.C.M.","family":"de Kok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116601_bib1","series-title":"WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention","author":"World Health O","year":"2021"},{"issue":"9916","key":"10.1016\/j.ejca.2026.116601_bib2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116601_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.35403","article-title":"Technical, legal and ethical framework of cancer audit in cervical screening - Summary of best practices for organised programmes delineated through an expert group consultation","author":"Chandran","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.116601_bib4","first-page":"2077","article-title":"Using audit and feedback to health professionals to improve the quality and safety of health care","author":"Flottorp","year":"2010","journal-title":"World Health Organ"},{"key":"10.1016\/j.ejca.2026.116601_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6600974","article-title":"Benefit of cervical screening at different ages: evidence from the UK audit of screening histories","author":"Sasieni","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2026.116601_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pvr.2015.06.006","article-title":"European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination","volume":"1","author":"von Karsa","year":"2015","journal-title":"Papillomavirus Res"},{"issue":"1","key":"10.1016\/j.ejca.2026.116601_bib7","first-page":"19","article-title":"Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"key":"10.1016\/j.ejca.2026.116601_bib8","unstructured":"Statistics CBo. Life expectancy; gender, age (per year and five-year period). 2024."},{"key":"10.1016\/j.ejca.2026.116601_bib9","unstructured":"Statistics CBo. Immigration and emigration; nationality, age, and gender. 2024."},{"key":"10.1016\/j.ejca.2026.116601_bib10","unstructured":"(RIVM) RvVeM. Vaccinatiegraad Rijksvaccinatieprogramma Nederland Verslagjaar 2025, 2025."},{"key":"10.1016\/j.ejca.2026.116601_bib11","doi-asserted-by":"crossref","DOI":"10.21105\/joss.01317","article-title":"lifelines: survival analysis in Python","volume":"4","author":"Davidson-Pilon","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.ejca.2026.116601_bib12","doi-asserted-by":"crossref","first-page":"a1754","DOI":"10.1136\/bmj.a1754","article-title":"Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study","volume":"337","author":"Dillner","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2026.116601_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068776","article-title":"Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data","volume":"377","author":"Rebolj","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ejca.2026.116601_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000515912","article-title":"Nationwide rereview of normal cervical cytologies before high-grade cervical lesions or before invasive cervical cancer","volume":"65","author":"Edvardsson","year":"2021","journal-title":"Acta Cytol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116601_bib15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/ijc.34723","article-title":"Long-term follow-up of cervical cancer incidence after normal cytological findings","volume":"154","author":"Wang","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.116601_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105237","article-title":"Improving human papillomavirus (HPV) testing in the cervical cancer elimination era: The 2021 HPV LabNet international proficiency study","volume":"154","author":"Arroyo Muhr","year":"2022","journal-title":"J Clin Virol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116601_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/0969141319864991","article-title":"The impact of knowledge of HPV positivity on cytology triage in primary high-risk HPV screening","volume":"26","author":"Aitken","year":"2019","journal-title":"J Med Screen"},{"issue":"6","key":"10.1016\/j.ejca.2026.116601_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ajog.2011.06.101","article-title":"Prior knowledge of HPV status improves detection of CIN2+ by cytology screening","volume":"205","author":"Benoy","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116601_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/ajcp\/aqx163","article-title":"Influence of prior knowledge of human papillomavirus status on the performance of cytology screening","volume":"149","author":"Martins","year":"2018","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/j.ejca.2026.116601_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju423","article-title":"Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial","volume":"107","author":"Bergeron","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ejca.2026.116601_bib21","doi-asserted-by":"crossref","first-page":"e886","DOI":"10.1016\/S2468-2667(24)00218-4","article-title":"Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden","volume":"9","author":"Wang","year":"2024","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.ejca.2026.116601_bib22","unstructured":"RIVM. Monitor Dutch cervical cancer screening programme 2022, 2023."},{"issue":"14","key":"10.1016\/j.ejca.2026.116601_bib23","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice","volume":"97","author":"Khan","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ejca.2026.116601_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J Low Genit Trac Dis"},{"key":"10.1016\/j.ejca.2026.116601_bib25","unstructured":"Australia C.C. National cervical screening program: management of oncogenic HPV types 16 and\/or 18. 2022. https:\/\/www.cancer.org.au\/clinical-guidelines\/cervical-cancer\/cervical-cancer-screening\/management-of-oncogenic-hpv-test-results\/oncogenic-hpv-types-16-and-or-18 (accessed 09-06-2025."},{"issue":"3","key":"10.1016\/j.ejca.2026.116601_bib26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ygyno.2020.12.038","article-title":"Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: a modelling study","volume":"160","author":"Kaljouw","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2026.116601_bib27","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/ijc.35289","article-title":"Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and\/or HPV genotyping in HPV positive women with low-grade cytology from a population-based Dutch primary HPV screening trial","volume":"156","author":"Verhoef","year":"2025","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116601_bib28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41416-021-01614-4","article-title":"Risk-stratification of HPV-positive women with low-grade cytology by FAM19A4\/miR124-2 methylation and HPV genotyping","volume":"126","author":"Dick","year":"2022","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2026.116601_bib29","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.33320","article-title":"Methylation markers FAM19A4 and miR124\u20132 as triage strategy for primary human papillomavirus screen positive women: a large European multicenter study","volume":"148","author":"Bonde","year":"2021","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2026.116601_bib30","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1038\/s41591-024-03014-6","article-title":"Cervical cancer screening using DNA methylation triage in a real-world population","volume":"30","author":"Schreiberhuber","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2026.116601_bib31","unstructured":"RIVM. Monitor Dutch cervical cancer screening programme 2023, 2024."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926003813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:33:43Z","timestamp":1777599223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926003813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"alternative-id":["S0959804926003813"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116601","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term cervical cancer risk following negative hrHPV-based versus negative cytology-based screening: A population-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116601"}}